Ballentine Partners LLC bought a new stake in Absci Co. (NASDAQ:ABSI – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 10,424 shares of the company’s stock, valued at ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in ...

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...

We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going ...

Equities research analysts at Needham & Company LLC assumed coverage on shares of Absci (NASDAQ:ABSI – Get Free Report) in a ...

Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug ...

In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other medical AI stocks. Investments in the global healthcare industry have ramped up ...